别嘌呤醇对慢性肾脏病非透析患者治疗作用的系统评价  

The meta analysis about using allopurinol on patients with chronic kidney disease without dialysis

作　　者：冯婕[1] 鄂静[2,3] 孔冉冉 解立怡[1] 余晓洋[1] 董红娟[1] FENG Jie;E Jing;KONG Ranran;XIE Liyi;YU Xiaoyang;DONG Hongjuan(Department of Nephrology,the First Affiliated Hospital of Xi'an Jiaotong University,Xi'an 710061,Shaanxi Province,China;Department of Nephrology,People's Hospital of Ningxia Hui Autonomous Region,Yinchuan 750002,Ningxia Hui Autonomous Region,China;First Clinical Medical College,Northwest University for Nationalities,Yinchuan 730030,Ningxia Hui Autonomous Region,China;Department of Thoracic Surgery,the Second Affiliated Hospital of Xi'an Jiaotong University,Xi'an 710004,Shaanxi Province,China)

机构地区：[1]西安交通大学医学院第一附属医院肾内科,陕西西安710061 [2]宁夏回族自治区人民医院肾内科,宁夏银川750002 [3]西北民族大学第一临床医学院,宁夏银川730030 [4]西安交通大学医学院第二附属医院胸外科,陕西西安710004

出　　处：《世界临床药物》2021年第8期648-657,共10页World Clinical Drug

基　　金：国家自然科学基金青年科学基金项目(82100718);西北民族大学中央高校基本科研资金项目(31920160104);陕西省自然科学基础研究计划一般项目(2018JM7120);陕西省自然科学基础研究计划一般项目(2017JM8046);宁夏自然科学基金(2020AAC03332)。

摘　　要：目的探讨别嘌呤醇在慢性肾脏病(chronic kidney disease,CKD)非透析患者中的治疗作用。方法通过检索电子数据库,收集别嘌呤醇与CKD相关资料,研究别嘌呤醇对CKD进展的影响。结果对纳入的14篇文献、1319例患者进行荟萃分析,并采用RevMan5.3软件进行meta分析。结果显示,观察组肾功能优于对照组(P<0.05);观察组血肌酐水平较对照组低,肾小球滤过率更高(P<0.05);观察组收缩压低于对照组(P<0.05);两组不良反应发生率、透析例数差异无统计学意义(P>0.05)。结论别嘌呤醇对CKD非透析患者延缓肾脏疾病进展有益且安全,但仍需大量前瞻性、高质量临床研究进一步证实,以获得更多循证医学证据。Objective To investigate the therapeutic effect of allopurinol on non-dialysis patients with chronic kidney disease(CKD).Methods By searching electronic database,the related data of allopurinol and CKD were collected to study the effect of allopurinol on the progress of CKD.Results A meta analysis of 14 articles and 1319 patients were performed by RevMan5.3 software.The results showed that the renal function of the treatment group was better than that of the control group(P<0.05).The serum creatinine level of the treatment group was lower than that of the control group,and the glomerular filtration rate was higher in the treatment group(P<0.05).The systolic blood pressure of the treatment group was lower than that of the control group(P<0.05).There was no significant difference in the incidence of adverse reactions and the number of dialysis patients between the two groups(P>0.05).Conclusion Allopurinol is beneficial and safe in delaying the progression in non-dialysis CKD patients,but it still needs to be further confirmed by a large number of prospective and high-quality clinical studies to obtain more evidence-based medicine evidence.

关 键 词：别嘌呤醇 慢性肾脏病 肾衰竭 肾功能不全 荟萃分析 

分 类 号：R979.5[医药卫生—药品] R692[医药卫生—药学]